Seattle Genetics
AcquiredPfizer: One of the world's premier biopharmaceutical companies
- Headquarters
- Seattle/Bothell, Washington
- Employees
- 1001–5000
- Founded
- 1998
- Business Model
- B2B
- Website
- seagen.com
- Total Funding
- $1.0B
- Valuation
- $204.8MMar 2001
- Last Round
- $1.0B Corporate RoundSep 2020
- Rounds
- 4
About
Seattle Genetics (later rebranded as Seagen) was a Bothell, Washington-based biotechnology company specializing in developing antibody-drug conjugates (ADCs) for cancer treatment. Founded in 1998, the company pioneered ADC technology, which links cancer-targeting antibodies to potent chemotherapy drugs, enabling precision delivery to tumor cells. Seagen was acquired by Pfizer in December 2023 for approximately $43 billion.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...
Specialty therapeutics company focused on gastrointestinal and hepatology diseases and programs
Clinical-stage biotech developing innovative sustained-release therapeutics for serious retinal d...
Biotechnology company developing new medicines to treat rare disorders of calcification with init...
Clinical-stage biopharmaceutical company developing small-molecule therapies for serious diseases...
Azenta Life Sciences provides automated sample management, storage solutions, and genomics servic...